The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 22, 2017
Filed:
Jun. 24, 2015
Applicant:
Nature Technology Corporation, Lincoln, NE (US);
Inventor:
James A. Williams, Lincoln, NE (US);
Assignee:
NATURE TECHNOLOGY CORPORATION, Lincoln, NE (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/85 (2006.01); A61K 48/00 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01); C12N 15/70 (2006.01); C12N 15/113 (2010.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01); C07K 14/005 (2006.01); C12N 15/11 (2006.01); C12N 15/117 (2010.01);
U.S. Cl.
CPC ...
A61K 48/0066 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); C07K 14/005 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 15/117 (2013.01); C12N 15/85 (2013.01); A61K 48/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55561 (2013.01); C12N 2310/11 (2013.01); C12N 2310/111 (2013.01); C12N 2310/17 (2013.01); C12N 2310/532 (2013.01); C12N 2320/30 (2013.01); C12N 2320/50 (2013.01); C12N 2710/10322 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16134 (2013.01); C12N 2800/106 (2013.01); C12N 2800/107 (2013.01); C12N 2830/00 (2013.01);
Abstract
Improved DNA vaccine plasmids are disclosed that contain novel immunostimulatory RNA compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short RNA based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation. These vectors are utilized in immunization to elicit improved immune responses or therapy to induce type 1 interferon production.